Palbociclib, Irinotecan, and Temozolomide in Ewing Sarcoma
Contact
Description
The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma and when given in combination with topotecan and cyclophosphamide in patients with neuroblastoma.
Eligibility and criteria
IRB Number:
19-016357
Eligible age range:
Clinical trial phase:
Phase II
Official title:
Related specialties
Related conditions

We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.